5th Cir blocks mifepristone mail; SCOTUS Alito stay preserves access [developing]
Key Questions
What did the 5th Circuit rule on mifepristone?
The 5th Circuit unanimously blocked FDA mailing and telehealth for mifepristone nationwide post-Dobbs in LA on May 1. This affects Duncan v. FDA.
How did SCOTUS respond to the 5th Circuit ruling?
SCOTUS issued an Alito administrative stay, blocking restrictions until May 11. It preserves temporary access amid Danco/GenBioPro appeals.
Which states are stockpiling mifepristone?
Washington is stockpiling meds. Restrictions impact ID/KS/MO/FL/TX where 63% of abortions are medical.
What amicus efforts support blocking restrictions?
MA AG and 22 states/DC urged SCOTUS to block; over 250 Democrats filed amicus briefs. Comstock Act and RFK Jr. are referenced.
What do multiple stays confirm?
Multiple stays preserve mail/telehealth/pharmacy access temporarily. This chills overall access.
What echoes Chevron in this case?
The case involves agency deference questions, echoing Chevron. FDA approvals are central.
When to watch for SCOTUS certiorari?
Watch SCOTUS cert/response by May 7. Full review on LA v. FDA is pending.
What is the broader impact on abortion access?
The rulings temporarily maintain access but signal ongoing challenges post-Dobbs. Med abortions comprise 63% nationally.
Unanimous 5th Cir nationwide block FDA mailing/telehealth (Duncan post-Dobbs LA; May 1); SCOTUS Alito admin stay confirmed blocks appeals court restrictions to May 11 (Danco/GenBioPro apps pause, LA v. FDA; WA stockpiling meds; 63% med abortions, ID/KS/MO/FL/TX; Comstock/RFK Jr.; MA AG 22 states/DC urge block; 250+ Dems amicus); multiple stays confirm temp preservation of mail/telehealth/pharmacy access; chills access; agency deference/Chevron echoes. Watch SCOTUS cert/response May 7.